A great many new and varied approaches to clinical trial management are being adopted during the COVID-19 pandemic through the help of virtualisation tools, strong partnerships, and regulatory guidance. Despite the upheaval this year and last, there appears to be a silver lining largely due to the systemic changes leading to the remarkably quick development in adapting trials to accommodate different environments and the incredible speed at which COVID-19 vaccines have been developed and administered. Regulatory guidance has accommodated this abrupt shift. Jennifer Bradford and Sheelagh Aird at PHASTAR, will cover the key factors needed prior to adapting to patient-centric clinical trials.